查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570643

醫藥品無菌填充製造市場(第2版):2035年前的產業趨勢與全球預測-所提供無菌填充服務形式，各最後製劑類型，API滴定率，各一次用包裝容器類型，各產業規模，不同企業規模，各地區，主要加入企業

Fill Finish Pharmaceutical Contract Manufacturing Market (2nd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Fill Finish Service Offered, Type of Primary Packaging Container, Regions and Leading Players
出版日期: | 出版商: Roots Analysis | 英文 340 Pages | 商品交期: 最快1-2個工作天內

價格

到 2024 年，藥品無菌灌裝製造市場規模預計將達到 72 億美元，到 2035 年的預測期間複合年增長率預計將達到 4.8%。

小分子的無菌填充過程是下游產品加工的最後一步，其中配製的藥物與必要的賦形劑和穩定劑相結合。純化的製劑被轉移到無菌容器中，例如玻璃瓶、預裝注射器、藥筒和安瓿，以進行測試、貼標籤和包裝。根據最近的研究，小分子藥物佔目前治療管線的近90%。 2023年，FDA核准的55種藥物中，61%將是小分子藥物，較2021年的56%及2022年的57%穩定成長。

無菌填充被認為是藥品製造中最重要的製程之一。此階段的無菌對於確保產品品質和病人安全以及維持藥物的藥理功效至關重要。然而，新的小分子製劑的無菌填充過程需要特殊的設備和專業知識，這增加了製造成本。這種資本投資的增加對於管理資源有限的藥物開發公司來說是一個課題，許多公司正在考慮將其製造業務外包給合約製造組織（CMO）或合約開發和製造組織（CDMO）。小分子藥物的不斷增長和複雜的管道以及對專業知識的需求正在推動製藥行業對無菌填充和服務的需求。此外，隨著對品質和高生產力策略的日益重視，人工智慧和機器人等先進技術的採用預計將鼓勵對該領域的進一步投資，並推動灌裝成品藥品合約製造市場的成長。

本報告提供全球醫藥品無菌填充製造市場相關調查，提供市場概要，以及所提供無菌填充各服務形式，各一次用包裝容器類型，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 調查手法

第3章 市場動態

第4章 經濟以及其他的計劃特有的考慮事項

第5章 摘要整理

第6章 簡介

第7章 市場形勢

第8章 企業簡介:北美的服務供應商

第9章 企業簡介:歐洲的服務供應商

第10章 企業簡介:亞太地區的服務供應商

第11章 企業簡介:其他地區的服務供應商

第12章 企業競爭力分析

第13章 容量分析

第14章 案例研究:無菌填充工作的機器人系統

第15章 案例研究:無菌填充用的RTU包裝零件

第16章 對市場的影響分析:促進因素，阻礙因素，機會，課題

  • 章概要
  • 市場促進因素
  • 市場阻礙因素
  • 市場機會
  • 市場課題
  • 結論

第17章 全球醫藥品無菌填充製造市場

第18章 醫藥品無菌填充製造市場，所提供無菌填充服務形式

第19章 醫藥品無菌填充製造市場，各最後製劑類型

第20章 醫藥品無菌填充製造市場，API滴定率

第21章 醫藥品無菌填充製造市場，各一次用包裝容器類型

第22章 醫藥品無菌填充製造市場，各產業規模

第23章 醫藥品無菌填充製造市場，不同企業規模

第24章 醫藥品無菌填充製造市場，各地區

第25章 醫藥品無菌填充製造市場，各主要企業

第26章 結論

第27章 執行洞察

第28章 附錄I:表格形式資料

第29章 附錄II:企業及團體一覽

Product Code: RA100231

The Fill Finish Pharmaceutical Contract Manufacturing Market is valued at USD 7.2 billion in 2024, and growing at a CAGR of 4.8% during the forecast period till 2035.

The fill-finish process for small molecules represents the final step in downstream product processing, where the formulated drug is combined with essential excipients and stabilizers. The bulk purified formulation is then transferred into pre-sterilized containers, such as glass vials, prefilled syringes, cartridges, or ampoules for inspection, labeling, and packaging. Recent studies show that small molecule drugs constitute nearly 90% of the current therapeutics pipeline. In 2023, 61% of the 55 FDA-approved drugs were small molecules, reflecting a steady rise from 56% in 2021 and 57% in 2022.

Sterile fill-finish is recognized as one of the most critical steps in pharmaceutical production. Aseptic conditions during this stage are essential for ensuring both product quality and patient safety, as well as maintaining the pharmacological effectiveness of the drug. However, the fill-finish process for novel small molecule formulations requires specialized equipment and expertise, driving up production costs. This increase in capital expenditure presents challenges for drug developers with limited resources, pushing many to outsource manufacturing operations to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). The growing pipeline of small molecule drugs, their increasing complexity, and the need for specialized expertise is driving demand for fill-finish services in the pharmaceutical industry. Additionally, with a stronger emphasis on quality and multi-product strategies, the adoption of advanced technologies, such as artificial intelligence and robotics, is expected to fuel further investment in this area, promoting growth in the fill-finish pharmaceutical contract manufacturing market.

Key Market Segments

Type of Fill Finish Service Offered

  • Aseptic Filling
  • Blow-Fill-Seal
  • Terminal Sterilization

Type of FDF

  • Generic FDF
  • Originator FDF

API Potency

  • Low Potent API
  • High Potent API

Type of Primary Packaging Container

  • Ampoules
  • Cartridges
  • Prefilled Syringe
  • Vials
  • Other Containers

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small and Mid-sized Companies
  • Large / Very Large Companies

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa

Research Coverage:

  • A general overview of the fill-finish pharma contract manufacturing market, encompassing the types of fill finishing processes, need for outsourcing small molecules-related operations, role of contract manufacturers in the small molecules industry, key considerations while selecting a fill finish service provider. Further, the chapter discusses the advantages and risks associated with contracting fill-finish operations. In addition, the chapter highlights the likely future trends and the potential of this industry.
  • A detailed assessment of the current market landscape, featuring an in-depth examination of the leading companies engaged in offering contract manufacturing services for small molecules, including a detailed analysis based on several relevant parameters, which include, year of establishment, company size (based on number of employees), location of headquarters, location of manufacturing facility, scale of operation (preclinical, clinical and commercial), type of fill finish service offered (aseptic filling, blow-fill-seal and terminal sterilization), type of finishing service offered (labeling and packaging, and visual inspection) type of packaging format (ampoules, bags, blisters, box, cartons, cartridges, jars, pillow packs, pouches, pre-filled syringes, sachet, stick packs, tubes, vials and others), type of finished dosage form (liquids, oral solids, semi-solids and oral solids), degree of automation (fully automated, semi-automated / manual).
  • An elaborative set of profiles of prominent players in small molecule fill finish contract manufacturing companies located in North America, highlighting information on their location of headquarters, year of establishment, company size (in terms of number of employees), key executives, financial information (if available), service portfolio, recent developments, and an informed future perspective.
  • An exhaustive set of profiles of leading players in small molecule fill finish contract manufacturing companies located in Europe, featuring information on their location of headquarters, year of establishment, company size (in terms of number of employees), key executive, financial information (if available), service portfolio, recent developments, and an informed future outlook.
  • A comprehensive set of profiles of prominent players in small molecule fill finish contract manufacturing companies based in Asia-Pacific, featuring information on their location of headquarters, year of establishment, company size (in terms of number of employees), key executive, financial information (if available), service portfolio, recent developments, and an informed future outlook.
  • An elaborative set of profiles of prominent players in small molecule fill finish contract manufacturing companies based in the rest of the world, featuring information on their location of headquarters, year of establishment, company size (in terms of number of employees), key executive, financial information (if available), service portfolio, recent developments, and an informed future outlook.
  • An elaborate input on the key players in this domain, on the basis of certain relevant parameters, such as company strength (in terms of years of experience and company size), portfolio strength (in terms of type of filling service offered, type of finishing service offered, number of packaging formats, number of dosage forms, and scale of operation) and portfolio diversity (in terms of degree of automation).
  • Details on the estimated global annual small molecule fill finish capacity, based on information reported by various industry stakeholders in the public domain. The analysis underlines the distribution of the available capacity for various packaging containers used (ampoules, cartridges, syringes and vials) based on company size (small, mid-sized, and large and very large firms) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
  • A case study emphasizing the benefits of utilizing robotic / automated equipment for aseptic fill finish processes. Further, it provides a list of equipment manufacturers offering robots suitable for pharmaceutical operations.
  • A case study highlighting the role of ready-to-use packaging containers in aseptic fill finish operations. It also provides a list of suppliers providing ready-to-use components.
  • An in-depth analysis of the factors that can impact the growth of the fill finish pharmaceutical contract manufacturing market. It also features information on key drivers, potential restraints, emerging opportunities and existing challenges within the market and has been provided in the report.
  • A comprehensive estimate of the current market size and the future growth potential of the fill finishes pharmaceutical contract manufacturing market over the next decade. Based on multiple parameters, such as likely adoption trends and through reliable secondary and primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035. The report also highlights the distribution of the current and forecasted opportunity within the industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the fill finish pharmaceutical contract manufacturing market growth.
  • Detailed projections of the current and future opportunity for small molecule fill finish contract manufacturing companies across various types of fill finish services offered, such as aseptic filling, blow-fill-seal and terminal sterilization.
  • Detailed projections of the current and future opportunity for contract manufacturers in the fill finish pharmaceutical contract manufacturing market across various types of FDF, such as generic FDF and originator FDF.
  • Detailed projections of the current and future opportunity for contract manufacturers in the fill finish pharmaceutical contract manufacturing industry across various type of API potency, such as low potent API and high potent API.
  • Detailed projections of the current and future opportunity for small molecule fill finish contract manufacturers across various types of primary packaging containers, such as ampoules, cartridges, prefilled syringes, vials and other containers.
  • Detailed projections of the current and future opportunity for contract manufacturers in the fill finish pharmaceutical contract manufacturing market across scale of operation, such as clinical and commercial.
  • Detailed projections of the current and future opportunity for contract manufacturers in pharmaceutical fill finish manufacturing market across different company sizes, such as small and mid-sized companies, and large / very large companies.
  • Detailed projections of the current and future opportunity for contract manufacturers in the fill finish pharmaceutical contract manufacturing industry across geographical regions, such as North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa.
  • Detailed projections of the leading players in the pharmaceutical fill finish manufacturing market based on several relevant parameters.

Key Benefits of Buying this Report

  • The report offers valuable insights into revenue estimation for both the overall market and its sub-segments, in order to empower market leaders and newcomers with critical information requisite for establishing their footprint in the industry.
  • The report can be utilized by stakeholders to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a comprehensive view on the Fill Finish Pharmaceutical Contract Manufacturing Market, covering essential information on significant market drivers, barriers, opportunities, and challenges.

Key Companies Profiled

  • Alcami
  • Amanta Healthcare
  • Aurigene Pharmaceutical Services
  • Batterjee Pharma
  • Burrard Pharmaceuticals
  • Curida
  • Eriochem
  • Fresenius Kabi
  • GlaxoSmithKline
  • Nextar Chempharma Solutions
  • Pfizer CentreOne
  • Plastikon Healthcare
  • Procaps
  • Recipharm

ROMMELAG CMO

  • Sharp
  • Sypharma
  • Teva Pharmaceuticals
  • WuXi AppTec

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Key Market Segmentation
  • 3.7. Robust Quality Control
  • 3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Overview of Major Currencies Affecting the Market
      • 4.2.2.2. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Exchange Impact
      • 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Introduction to Fill / Finish Services for Small Molecules
    • 6.2.1. Aseptic Filling
    • 6.2.2. Terminal Sterilization
    • 6.2.3. Blow-Fill-Seal Technology
  • 6.3. Need for Outsourcing Small Molecules-related Operations
  • 6.4. Role of Contract Manufacturers in the Small Molecules Industry
  • 6.5. Key Considerations while selecting a Fill / Finish Service Provider
  • 6.6. Advantages of Outsourcing Fill / Finish Services
  • 6.7. Risks and Challenges of Outsourcing Fill / Finish Operations
  • 6.8. Future Perspectives

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Small Molecules Fill / Finish Service Providers: Overall Market Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Location of Fill / Finish Facilities
    • 7.2.5. Analysis by Scale of Operation
    • 7.2.6. Analysis by Type of Filling Service Offered
    • 7.2.7. Analysis by Type of Finishing Service Offered
    • 7.2.8. Analysis by Type of Packaging Format Used
    • 7.2.9. Analysis by Type of Finished Dosage Form
    • 7.2.10. Analysis by Degree of Automation

8. COMPANY PROFILES: SERVICE PROVIDERS IN NORTH AMERICA

  • 8.1. Chapter Overview
  • 8.2. Leading Small Molecules Fill / Finish Service Providers based in North America
    • 8.2.1. Alcami
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. Pfizer CentreOne
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. Sharp Services
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
  • 8.3. Other Leading Small Molecules Fill / Finish Service Providers based in North America
    • 8.3.1. Burrard Pharmaceuticals
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 8.3.2. Plastikon Healthcare
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Small Molecules Fill / Finish Service Portfolio

9. COMPANY PROFILES: SERVICE PROVIDERS IN EUROPE

  • 9.1. Chapter Overview
  • 9.2. Leading Small Molecules Fill / Finish Service Providers based in Europe
    • 9.2.1. Fresenius Kabi
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Information
      • 9.2.1.3. Small Molecules Fill / Finish Service Portfolio
      • 9.2.1.4. Recent Developments and Future Outlook
    • 9.2.2. GlaxoSmithKline
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Information
      • 9.2.2.3. Small Molecules Fill / Finish Service Portfolio
      • 9.2.2.4. Recent Developments and Future Outlook
    • 9.2.3. Recipharm
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 9.2.3.3. Recent Developments and Future Outlook
  • 9.3. Other Leading Small Molecules Fill / Finish Service Providers based in Europe
    • 9.3.1. Curida
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 9.3.2. ROMMELAG CMO
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Small Molecules Fill / Finish Service Portfolio

10. COMPANY PROFILES: SERVICE PROVIDERS IN ASIA-PACIFIC

  • 10.1. Chapter Overview
  • 10.2. Leading Small Molecules Fill / Finish Service Providers based in Asia-Pacific
    • 10.2.1. Aurigene Pharmaceutical Services
      • 10.2.1.1. Company Overview
      • 10.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.1.3. Recent Developments and Future Outlook
    • 10.2.2. Sypharma
      • 10.2.2.1. Company Overview
      • 10.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.2.3. Recent Developments and Future Outlook
    • 10.2.3. WuXi AppTec
      • 10.2.3.1. Company Overview
      • 10.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.3.3. Recent Developments and Future Outlook
  • 10.3. Other Small Molecules Fill / Finish Service Providers based in Asia-Pacific
    • 10.3.1. Amanta Healthcare
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Small Molecules Fill / Finish Service Portfolio

11. COMPANY PROFILES: SERVICE PROVIDERS IN THE REST OF THE WORLD

  • 11.1. Chapter Overview
  • 11.2. Leading Small Molecules Fill / Finish Service Providers based in the Rest of the World
    • 11.2.1. Eriochem
      • 11.2.1.1. Company Overview
      • 11.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 11.2.1.3. Recent Developments and Future Outlook
    • 11.2.2. Teva Pharmaceutical Industries
      • 11.2.2.1. Company Overview
      • 11.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 11.2.2.3. Recent Developments and Future Outlook
  • 11.3. Other Small Molecules Fill / Finish Service Providers based in Rest of the World
    • 11.3.1. Batterjee Pharma
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 11.3.2. Procaps
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Small Molecules Fill / Finish Service Portfolio

12. COMPANY COMPETITIVENESS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Assumptions and Key Parameters
  • 12.3. Methodology
  • 12.4. Small Molecules Fill / Finish Service Providers based in North America
  • 12.5. Small Molecules Fill / Finish Service Providers based in Europe
  • 12.6. Small Molecules Fill / Finish Service Providers based in Asia-Pacific and Rest of the World

13. CAPACITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Global Annual Small Molecules Fill / Finish Capacity for Ampoules (Number of Units)
    • 13.2.1. Key Assumptions and Methodology
    • 13.2.2. Analysis by Company Size
    • 13.2.3. Analysis by Geography
      • 13.2.3.1. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in North America
      • 13.2.3.2. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in Europe
      • 13.2.3.3. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • 13.3. Global Annual Small Molecules Fill / Finish Capacity for Cartridges (Number of Units)
    • 13.3.1. Key Assumptions and Methodology
    • 13.3.2. Analysis by Company Size
    • 13.3.3. Analysis by Geography
      • 13.3.3.1. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in North America
      • 13.3.3.2. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in Europe
      • 13.3.3.3. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and the Rest of the World
  • 13.4. Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes (Number of Units)
    • 13.4.1. Key Assumptions and Methodology
    • 13.4.2. Analysis by Company Size
    • 13.4.3. Analysis by Geography
      • 13.4.3.1. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
      • 13.4.3.2. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
      • 13.4.3.3. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • 13.5. Global Annual Small Molecules Fill / Finish Capacity for Vials (Number of Units)
    • 13.5.1. Key Assumptions and Methodology
    • 13.5.2. Analysis by Company Size
    • 13.5.3. Analysis by Geography
      • 13.5.3.1. Analysis of Small Molecules Fill / Finish Capacity for Vials in North America
      • 13.5.3.2. Analysis of Small Molecules Fill / Finish Capacity for Vials in Europe
      • 13.5.3.3. Analysis of Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World

14. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS

  • 14.1. Chapter Overview
  • 14.2. Role of Robotic Systems in Fill / Finish Operations
    • 14.2.1. Types of Robots Used
    • 14.2.2. Key Considerations for Selecting Robotic Systems
  • 14.3. Companies Providing Robots for use in the Pharmaceutical Industry
  • 14.4. Companies Providing Isolator-based Aseptic Filling Systems
  • 14.5. Small Molecules Fill / Finish Service Providers: List of Equipment Used
  • 14.6. Concluding Remarks

15. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

  • 15.1. Chapter Overview
  • 15.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
    • 15.2.1. Advantages of Ready-to-Use Packaging Components
    • 15.2.2. Disadvantages of Ready-to-Use Packaging Components
  • 15.3. Companies Providing Ready-to-Use Packaging Components
  • 15.4. Concluding Remarks

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segmentations

18. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF FILL / FINISH SERVICE OFFERED

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Methodology
  • 18.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035
    • 18.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035
    • 18.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035
    • 18.3.3. Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035
  • 18.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of Fill / Finish Services Offered: Market Dynamics Assessment
    • 18.4.1. Penetration-Growth (P-G) Matrix
    • 18.4.2. Data Triangulation and Validation

19. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF FDF

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035
    • 19.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035
    • 19.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035
  • 19.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of FDF: Market Dynamics Assessment
    • 19.4.1. Penetration-Growth (P-G) Matrix
    • 19.4.2. Data Triangulation and Validation

20. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY API POTENCY

  • 20.1. Chapter Overview
  • 20.2. Assumptions and Methodology
  • 20.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035
    • 20.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035
    • 20.3.2. Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035
  • 20.4. Pharmaceutical Fill / Finish Manufacturing Market, by API Potency: Market Dynamics Assessment
    • 20.4.1. Penetration-Growth (P-G) Matrix
    • 20.4.2. Data Triangulation and Validation

21. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING CONTAINER

  • 21.1. Chapter Overview
  • 21.2. Assumptions and Methodology
  • 21.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035
    • 21.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035
    • 21.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035
    • 21.3.3. Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035
    • 21.3.4. Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035
    • 21.3.5. Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035
  • 21.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of Primary Packaging Container: Market Dynamics Assessment
    • 21.4.1. Penetration-Growth (P-G) Matrix
    • 21.4.2. Data Triangulation and Validation

22. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 22.1. Chapter Overview
  • 22.2. Assumptions and Methodology
  • 22.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035
    • 22.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035
    • 22.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035
  • 22.4. Pharmaceutical Fill / Finish Manufacturing Market, by Scale of Operation: Market Dynamics Assessment
    • 22.4.1. Penetration-Growth (P-G) Matrix
    • 22.4.2. Data Triangulation and Validation

23. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY COMPANY SIZE

  • 23.1. Chapter Overview
  • 23.2. Assumptions and Methodology
  • 23.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035
    • 23.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035
    • 23.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035
  • 23.4. Pharmaceutical Fill / Finish Manufacturing Market, by Company Size: Market Dynamics Assessment
    • 23.4.1. Penetration-Growth (P-G) Matrix
    • 23.4.2. Data Triangulation and Validation

24. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

  • 24.1. Chapter Overview
  • 24.2. Assumptions and Methodology
  • 24.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions, 2019, Current Year and 2035
    • 24.3.1. Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035
      • 24.3.1.1. Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035
      • 24.3.1.2. Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035
      • 24.3.1.3. Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035
      • 24.3.1.4. Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035
    • 24.3.2. Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035
      • 24.3.2.1. Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035
      • 24.3.2.2. Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035
      • 24.3.2.3. Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035
      • 24.3.2.4. Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035
      • 24.3.2.5. Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035
      • 24.3.2.6. Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035
    • 24.3.3. Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035
      • 24.3.3.1. Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035
      • 24.3.3.2. Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035
      • 24.3.3.3. Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035
      • 24.3.3.4. Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035
    • 24.3.4. Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035
    • 24.3.5. Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035
    • 24.3.6. Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035
  • 24.4. Pharmaceutical Fill / Finish Manufacturing Market, by Geographical Regions: Market Dynamics Assessment
    • 24.4.1. Penetration-Growth (P-G) Matrix
    • 24.4.2. Data Triangulation and Validation

25. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY LEADING PLAYERS

  • 25.1. Chapter Overview
  • 25.2. Leading Industry Players

26. CONCLUSION

27. EXECUTIVE INSIGHT

  • 27.1 Chapter Overview
  • 27.2. Bushu Pharmaceuticals
    • 27.2.1. Company Snapshot
    • 27.2.2. Interview Transcript: Tomoya Sato, Senior Executive Director, Global Sales and Marketing

28. APPENDIX I: TABULATED DATA

29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 Small Molecules Fill / Finish Service Providers: List of Companies
  • Table 7.2 Small Molecules Fill / Finish Service Providers: Information on Scale of Operation, Type of Filling Service Offered and Type of Finishing Service Offered
  • Table 7.3 Small Molecules Fill / Finish Service Providers: Information on Type of Packaging Format Used, Type of Finished Dosage Form and Degree of Automation
  • Table 8.1 Small Molecules Fill / Finish Service Providers in North America: List of Companies Profiled
  • Table 8.2 Alcami: Company Overview
  • Table 8.3 Alcami: Small Molecules Fill / Finish Service Portfolio
  • Table 8.4 Alcami: Recent Developments and Future Outlook
  • Table 8.5 Pfizer CentreOne: Company Overview
  • Table 8.6 Pfizer CentreOne: Small Molecules Fill / Finish Service Portfolio
  • Table 8.7 Sharp Services: Company Overview
  • Table 8.8 Sharp Services: Small Molecules Fill / Finish Service Portfolio
  • Table 8.9 Sharp Services: Recent Developments and Future Outlook
  • Table 8.10 Burrard Pharmaceuticals: Company Overview
  • Table 8.11 Burrard Pharmaceuticals: Small Molecules Fill / Finish Service Portfolio
  • Table 8.12 Plastikon Healthcare: Company Overview
  • Table 8.13 Plastikon Healthcare: Small Molecules Fill / Finish Service Portfolio
  • Table 9.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 9.2 Fresenius Kabi: Company Overview
  • Table 9.3 Fresenius Kabi: Small Molecules Fill / Finish Service Portfolio
  • Table 9.4 Fresenius Kabi: Recent Developments and Future Outlook
  • Table 9.5 GlaxoSmithKline: Company Overview
  • Table 9.6 GlaxoSmithKline: Small Molecules Fill / Finish Service Portfolio
  • Table 9.7 GlaxoSmithKline: Recent Developments and Future Outlook
  • Table 9.8 Recipharm: Company Overview
  • Table 9.9 Recipharm: Small Molecules Fill / Finish Service Portfolio
  • Table 9.10 Recipharm: Recent Developments and Future Outlook
  • Table 9.11 Curida: Company Overview
  • Table 9.12 Curida: Small Molecules Fill / Finish Service Portfolio
  • Table 9.13 ROMMELAG CMO: Company Overview
  • Table 9.14 ROMMELAG CMO: Small Molecules Fill / Finish Service Portfolio
  • Table 10.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 10.2 Aurigene Pharmaceutical Services: Company Overview
  • Table 10.3 Aurigene Pharmaceutical Services: Small Molecules Fill / Finish Service Portfolio
  • Table 10.4 Aurigene Pharmaceutical Services: Recent Developments and Future Outlook
  • Table 10.5 Sypharma: Company Overview
  • Table 10.6 Sypharma: Small Molecules Fill / Finish Service Portfolio
  • Table 10.7 Sypharma: Recent Developments and Future Outlook
  • Table 10.8 WuXi AppTec: Company Overview
  • Table 10.9 WuXi AppTec: Small Molecules Fill / Finish Service Portfolio
  • Table 10.10 WuXi AppTec: Recent Developments and Future Outlook
  • Table 10.11 Amanta Healthcare: Company Overview
  • Table 10.12 Amanta Healthcare: Small Molecules Fill / Finish Service Portfolio
  • Table 11.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 11.2 Eriochem: Company Overview
  • Table 11.3 Eriochem: Small Molecules Fill / Finish Service Portfolio
  • Table 11.4 Teva Pharmaceutical Industries: Company Overview
  • Table 11.5 Teva Pharmaceutical Industries: Small Molecules Fill / Finish Service Portfolio
  • Table 11.6 Teva Pharmaceutical Industries: Recent Developments and Future Outlook
  • Table 11.7 Batterjee Pharma: Company Overview
  • Table 11.8 Batterjee Pharma: Small Molecules Fill / Finish Service Portfolio
  • Table 11.9 Nextar Chempharma Solutions: Company Overview
  • Table 11.10 Nextar Chempharma Solutions: Small Molecules Fill / Finish Service Portfolio
  • Table 11.11 Procaps: Company Overview
  • Table 11.12 Procaps: Small Molecules Fill / Finish Service Portfolio
  • Table 13.1 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Ampoules (Sample Data Set)
  • Table 13.2 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Ampoules, by Company Size (Sample Dataset)
  • Table 13.3 Global Annual Small Molecules Fill / Finish Capacity for Ampoules, by Company Size (in terms of units)
  • Table 13.4 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Cartridges (Sample Data Set)
  • Table 13.5 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Cartridges, by Company Size (Sample Dataset)
  • Table 13.6 Global Annual Small Molecules Fill / Finish Capacity for Cartridges, by Company Size (in terms of units)
  • Table 13.7 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Prefilled Syringes (Sample Data Set)
  • Table 13.8 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Prefilled Syringes, by Company Size (Sample Dataset)
  • Table 13.9 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes, by Company Size (in terms of units)
  • Table 13.10 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Vials (Sample Data Set)
  • Table 13.11 Small Molecules Fill / Finish Service Providers: Average Capacity for Vials, by Company Size (Sample Dataset)
  • Table 13.12 Global Annual Small Molecules Fill / Finish Capacity for Vials: Total Capacity by Company Size (in terms of units)
  • Table 14.1 List of Companies Providing Robots for Use in Pharmaceutical Industry
  • Table 14.2 Isolator-based Aseptic Filling Systems: Information on Compatible Primary Container
  • Table 14.3 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
  • Table 15.1 List of Companies Providing Ready-to-Use Packaging Components
  • Table 25.1 Leading Industry Players: Based on the Annual Capacity Installed
  • Table 27.1 Bushu Pharmaceuticals: Company Overview
  • Table 28.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
  • Table 28.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
  • Table 28.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Table 28.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Table 28.5 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
  • Table 28.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service Offered
  • Table 28.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service Offered
  • Table 28.8 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Format Used
  • Table 28.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finished Dosage Form
  • Table 28.10 Small Molecules Fill / Finish Service Providers: Distribution by Degree of Automation
  • Table 28.11 Pfizer (parent company of Pfizer CentreOne): Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Table 28.12 Fresenius Kabi: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Table 28.13 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Table 28.14 WuXi AppTec: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion)
  • Table 28.15 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Company Size
  • Table 28.16 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
  • Table 28.17 Small Molecules Fill / Finish Capacity for Ampoules in North America
  • Table 28.18 Small Molecules Fill / Finish Capacity for Ampoules in Europe
  • Table 28.19 Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • Table 28.20 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Company Size
  • Table 28.21 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
  • Table 28.22 Small Molecules Fill / Finish Capacity for Cartridges in North America
  • Table 28.23 Small Molecules Fill / Finish Capacity for Cartridges in Europe
  • Table 28.24 Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
  • Table 28.25 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Company Size
  • Table 28.26 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Location of Fill / Finish Facility
  • Table 28.27 Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
  • Table 28.28 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
  • Table 28.29 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • Table 28.30 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Company Size
  • Table 28.31 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
  • Table 28.32 Small Molecules Fill / Finish Capacity for Vials in North America
  • Table 28.33 Small Molecules Fill / Finish Capacity for Vials in Europe
  • Table 28.34 Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World
  • Figure 28.35 Global Pharmaceutical Fill / Finish Manufacturing Market: Conservative, Base, Optimistic Scenario, till 2035 (USD Billion)
  • Table 28.36 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035 (USD Billion)
  • Table 28.37 Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035 (USD Billion)
  • Table 28.38 Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035 (USD Billion)
  • Table 25.39 Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035 (USD Billion)
  • Table 28.40 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035 (USD Billion)
  • Table 28.41 Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035 (USD Billion)
  • Table 28.42 Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035 (USD Billion)
  • Table 28.43 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035 (USD Billion)
  • Table 28.44 Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035 (USD Billion)
  • Table 28.45 Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035 (USD Billion)
  • Table 28.46 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035 (USD Billion)
  • Table 28.47 Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035 (USD Billion)
  • Table 28.48 Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035 (USD Billion)
  • Table 28.49 Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035 (USD Billion)
  • Table 28.50 Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035 (USD Billion)
  • Table 28.51 Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035 (USD Billion)
  • Table 28.52 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035 (USD Billion)
  • Table 28.53 Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035 (USD Billion)
  • Table 28.54 Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035 (USD Billion)
  • Table 28.55 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035 (USD Billion)
  • Table 28.56 Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035 (USD Billion)
  • Table 28.57 Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035 (USD Billion)
  • Table 28.58 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions 2019, Current Year and 2035 (USD Billion)
  • Table 28.59 Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035 (USD Billion)
  • Table 28.60 Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035 (USD Billion)
  • Table 28.61 Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035 (USD Billion)
  • Table 28.62 Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035 (USD Billion)
  • Table 28.63 Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035 (USD Billion)
  • Table 28.64 Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035 (USD Billion)
  • Table 28.65 Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035 (USD Billion)
  • Table 28.66 Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035 (USD Billion)
  • Table 28.67 Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035 (USD Billion)
  • Table 28.68 Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035 (USD Billion)
  • Table 28.69 Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035 (USD Billion)
  • Table 28.70 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035 (USD Billion)
  • Table 28.71 Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • Table 28.72 Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035 (USD Billion)
  • Table 28.73 Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035 (USD Billion)
  • Table 28.74 Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035 (USD Billion)
  • Table 28.75 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Table 28.76 Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • Table 28.77 Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035 (USD Billion)
  • Table 28.78 Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 3.3 Market Dynamics: Robust Quality Control
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Steps involved in Fill / Finish of Small Molecules
  • Figure 6.2 Blow-Fill-Seal Process
  • Figure 6.3 Key Considerations for Selecting a CMO Partner
  • Figure 6.4 Risks and Challenges of Outsourcing Fill / Finish Operations
  • Figure 7.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
  • Figure 7.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
  • Figure 7.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Figure 7.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Figure 7.5 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
  • Figure 7.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service Offered
  • Figure 7.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service Offered
  • Figure 7.8 Small Molecules Fill / Finish Service Providers: Analysis by Type of Packaging Format Used
  • Figure 7.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finished Dosage Form
  • Figure 7.10 Small Molecules Fill / Finish Service Providers: Distribution by Degree of Automation
  • Figure 8.1 Pfizer (parent company of Pfizer CentreOne): Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Figure 9.1 Fresenius: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Figure 9.2 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Figure 10.1 WuXi AppTec: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion)
  • Figure 12.1 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in North America
  • Figure 12.2 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in Europe
  • Figure 12.3 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in Asia-Pacific and Rest of the World
  • Figure 13.1 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Company Size
  • Figure 13.2 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
  • Figure 13.3 Small Molecules Fill / Finish Capacity for Ampoules in North America
  • Figure 13.4 Small Molecules Fill / Finish Capacity for Ampoules in Europe
  • Figure 13.5 Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • Figure 13.6 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Company Size
  • Figure 13.7 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
  • Figure 13.8 Small Molecules Fill / Finish Capacity for Cartridges in North America
  • Figure 13.9 Small Molecules Fill / Finish Capacity for Cartridges in Europe
  • Figure 13.10 Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
  • Figure 13.11 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Company Size
  • Figure 13.12 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Location of Fill / Finish Facility
  • Figure 13.13 Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
  • Figure 13.14 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
  • Figure 13.15 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • Figure 13.16 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Company Size
  • Figure 13.17 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
  • Figure 13.18 Small Molecules Fill / Finish Capacity for Vials in North America
  • Figure 13.19 Small Molecules Fill / Finish Capacity for Vials in Europe
  • Figure 13.20 Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World
  • Figure 14.1 Key Considerations for Selecting a Robotic Systems
  • Figure 14.2 Advantages of Using Robotic Systems
  • Figure 15.1 Key Drivers of Ready-to-Use Components
  • Figure 16.1 Pharmaceutical Fill / Finish Manufacturing: Market Drivers
  • Figure 16.2 Pharmaceutical Fill / Finish Manufacturing: Market Restraints
  • Figure 16.3 Pharmaceutical Fill / Finish Manufacturing: Market Opportunities
  • Figure 16.4 Pharmaceutical Fill / Finish Manufacturing: Market Challenges
  • Figure 17.1 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035 (USD Billion)
  • Figure 17.2 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035: Conservative Scenario (USD Billion)
  • Figure 17.3 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035: Optimistic Scenario (USD Billion)
  • Figure 18.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035
  • Figure 18.2 Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035 (USD Billion)
  • Figure 18.3 Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035 (USD Billion)
  • Figure 18.4 Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035 (USD Billion)
  • Figure 18.5 Penetration-Growth (P-G) Matrix: Type of Fill / Finish Service Offered
  • Figure 19.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035
  • Figure 19.2 Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035 (USD Billion)
  • Figure 19.3 Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035 (USD Billion)
  • Figure 19.4 Penetration-Growth (P-G) Matrix: Type of FDF
  • Figure 20.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035
  • Figure 20.2 Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035 (USD Billion)
  • Figure 20.3 Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035 (USD Billion)
  • Figure 20.4 Penetration-Growth (P-G) Matrix: API Potency
  • Figure 21.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035
  • Figure 21.2 Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035 (USD Billion)
  • Figure 21.3 Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035 (USD Billion)
  • Figure 21.4 Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035 (USD Billion)
  • Figure 21.5 Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035 (USD Billion)
  • Figure 21.6 Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035 (USD Billion)
  • Figure 21.7 Penetration-Growth (P-G) Matrix: Type of Primary Packaging Container
  • Figure 22.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035
  • Figure 22.2 Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035 (USD Billion)
  • Figure 22.3 Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035 (USD Billion)
  • Figure 22.4 Penetration-Growth (P-G) Matrix: Scale of Operation
  • Figure 23.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035
  • Figure 23.2 Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035 (USD Billion)
  • Figure 23.3 Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035 (USD Billion)
  • Figure 23.4 Penetration-Growth (P-G) Matrix: Company Size
  • Figure 24.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions 2019, Current Year and 2035
  • Figure 24.2 Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035 (USD Billion)
  • Figure 24.3 Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035 (USD Billion)
  • Figure 24.4 Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035 (USD Billion)
  • Figure 24.5 Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035 (USD Billion)
  • Figure 24.6 Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035 (USD Billion)
  • Figure 24.7 Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035 (USD Billion)
  • Figure 24.8 Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035 (USD Billion)
  • Figure 24.9 Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035 (USD Billion)
  • Figure 24.10 Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035 (USD Billion)
  • Figure 24.11 Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035 (USD Billion)
  • Figure 24.12 Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035 (USD Billion)
  • Figure 24.13 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035 (USD Billion)
  • Figure 24.14 Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • Figure 24.15 Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035 (USD Billion)
  • Figure 24.16 Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035 (USD Billion)
  • Figure 24.17 Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035 (USD Billion)
  • Figure 24.18 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 24.19 Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • Figure 24.20 Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035 (USD Billion)
  • Figure 24.21 Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035 (USD Billion)
  • Figure 24.22 Penetration-Growth (P-G) Matrix: Geographical Regions
  • Figure 26.1 Conclusion: Small Molecules Fill / Finish Service Providers Landscape
  • Figure 26.2 Conclusion: Capacity Analysis
  • Figure 26.3 Conclusion: Market Forecast and Opportunity Analysis (I/II)
  • Figure 26.4 Conclusion: Market Forecast and Opportunity Analysis (II/II)